TW202338088A - 活化抗肌萎縮蛋白相關蛋白表達的寡核苷酸調節劑 - Google Patents

活化抗肌萎縮蛋白相關蛋白表達的寡核苷酸調節劑 Download PDF

Info

Publication number
TW202338088A
TW202338088A TW112102859A TW112102859A TW202338088A TW 202338088 A TW202338088 A TW 202338088A TW 112102859 A TW112102859 A TW 112102859A TW 112102859 A TW112102859 A TW 112102859A TW 202338088 A TW202338088 A TW 202338088A
Authority
TW
Taiwan
Prior art keywords
sarna
dystrophin
expression
gene
utrn
Prior art date
Application number
TW112102859A
Other languages
English (en)
Chinese (zh)
Inventor
姜武林
羅伯特 普雷斯
龍承 李
Original Assignee
大陸商中美瑞康核酸技術(南通)研究院有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商中美瑞康核酸技術(南通)研究院有限公司 filed Critical 大陸商中美瑞康核酸技術(南通)研究院有限公司
Publication of TW202338088A publication Critical patent/TW202338088A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW112102859A 2022-01-20 2023-01-19 活化抗肌萎縮蛋白相關蛋白表達的寡核苷酸調節劑 TW202338088A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/CN2022/072958 2022-01-20
CN2022072958 2022-01-20

Publications (1)

Publication Number Publication Date
TW202338088A true TW202338088A (zh) 2023-10-01

Family

ID=87347803

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112102859A TW202338088A (zh) 2022-01-20 2023-01-19 活化抗肌萎縮蛋白相關蛋白表達的寡核苷酸調節劑

Country Status (10)

Country Link
US (1) US20250101421A1 (cg-RX-API-DMAC7.html)
EP (1) EP4466359A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025504474A (cg-RX-API-DMAC7.html)
KR (1) KR20250005567A (cg-RX-API-DMAC7.html)
CN (1) CN118829728A (cg-RX-API-DMAC7.html)
AU (1) AU2023209973A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249545A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024008939A (cg-RX-API-DMAC7.html)
TW (1) TW202338088A (cg-RX-API-DMAC7.html)
WO (1) WO2023138502A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025201529A1 (en) * 2024-03-29 2025-10-02 Ractigen Therapeutics Compounds for synthesizing modified small activating rna molecules, modified small activating rna molecules and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916532B2 (en) * 2008-04-28 2014-12-23 The Trustees Of The University Of Pennsylvania Methods for enhancing utrophin production via inhibition of microRNA
EP2427554B1 (en) * 2009-05-08 2016-11-16 CuRNA, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
CN104540946A (zh) * 2012-05-16 2015-04-22 Rana医疗有限公司 用于调节utrn表达的组合物和方法
US20170044540A1 (en) * 2014-04-22 2017-02-16 Mina Therapeutics Limited Sarna compositions and methods of use
WO2019183005A1 (en) * 2018-03-19 2019-09-26 The Trustees Of The University Of Pennsylvania 2'f-ana-let7 mediated utrophin upregulation for dmd therapy
WO2021230385A1 (en) * 2020-05-15 2021-11-18 Astellas Pharma Inc. Method for treating muscular dystrophy by targeting utrophin gene

Also Published As

Publication number Publication date
MX2024008939A (es) 2024-07-29
CA3249545A1 (en) 2023-07-27
US20250101421A1 (en) 2025-03-27
KR20250005567A (ko) 2025-01-09
CN118829728A (zh) 2024-10-22
EP4466359A4 (en) 2026-07-01
AU2023209973A1 (en) 2024-09-05
EP4466359A1 (en) 2024-11-27
JP2025504474A (ja) 2025-02-12
WO2023138502A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
US20250333734A1 (en) Antisense oligonucleotides for the treatment of Stargardt disease
JP6604544B2 (ja) エクソンスキッピング効果を有する二本鎖アンチセンス核酸
US10421963B2 (en) Oligonucleotide therapy for leber congenital amaurosis
US20180237775A1 (en) Antisense oligonucleotides and uses thereof
WO2024001172A1 (en) Oligonucleotide modulators activating complement factor h expression
US20200024601A1 (en) Antisense oligonucleotides to treat dystrophic epidermoylsis bullosa
EP4367244A1 (en) Oligonucleotide-based delivery vehicle for oligonucleotides agents and methods of use thereof
TW202039848A (zh) 肌肉生長抑制素訊號傳導抑制劑
JP2026509175A (ja) Sod1を標的とするオリゴヌクレオチド
AU2020411964A1 (en) Antisense nucleic acid that induces skipping of exon 50
CN115210376A (zh) 诱导外显子51的跳读的反义核酸
TW202417013A (zh) 小活化核酸分子及其在治療遺傳性血管性水腫中的用途
WO2023138502A1 (en) Oligonucleotide modulators activating utrophin expression
HK40118443A (en) Oligonucleotide modulators activating utrophin expression
WO2024183714A1 (en) Oligonucleotide modulators activating factor vii expression and use thereof in treatment of hemophilia
HK40122862A (en) Oligonucleotide modulators activating complement factor h expression
TW202608455A (zh) 啟動凝血因子vii表達的寡核苷酸調節劑及其在血友病治療中的應用
CA2999192C (en) Antisense oligonucleotides hybridizing with a key element of the polyadenylation region of a dux4 pre-mrna and uses thereof
HK40119190A (en) Small activating nucleic acid molecule and use thereof in treatment of hereditary angioedema
WO2025237990A1 (en) Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2024254092A2 (en) Methods and compositions for treating neurological diseases and disorders and cancers
HK40082220A (en) Antisense nucleic acid inducing skipping of exon 51
KR20220155585A (ko) Sirt1 발현을 사용하는 진단 방법